TWI708787B - Pd-1促效劑抗體及其用途 - Google Patents

Pd-1促效劑抗體及其用途 Download PDF

Info

Publication number
TWI708787B
TWI708787B TW108105310A TW108105310A TWI708787B TW I708787 B TWI708787 B TW I708787B TW 108105310 A TW108105310 A TW 108105310A TW 108105310 A TW108105310 A TW 108105310A TW I708787 B TWI708787 B TW I708787B
Authority
TW
Taiwan
Prior art keywords
antibody
seq
acid sequence
amino acid
human
Prior art date
Application number
TW108105310A
Other languages
English (en)
Chinese (zh)
Other versions
TW201942133A (zh
Inventor
清 柴
意青 丰
克麗斯汀 佩吉 紐本
史帝芬妮 瑪莉 楚樂
佩卓 瓦迪若
皮埃 波林娜 亞奇
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW201942133A publication Critical patent/TW201942133A/zh
Application granted granted Critical
Publication of TWI708787B publication Critical patent/TWI708787B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW108105310A 2018-03-02 2019-02-18 Pd-1促效劑抗體及其用途 TWI708787B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637643P 2018-03-02 2018-03-02
US62/637,643 2018-03-02

Publications (2)

Publication Number Publication Date
TW201942133A TW201942133A (zh) 2019-11-01
TWI708787B true TWI708787B (zh) 2020-11-01

Family

ID=65686121

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108105310A TWI708787B (zh) 2018-03-02 2019-02-18 Pd-1促效劑抗體及其用途

Country Status (26)

Country Link
US (1) US10493148B2 (https=)
EP (1) EP3759139A1 (https=)
JP (3) JP7071521B2 (https=)
KR (2) KR102536014B1 (https=)
CN (4) CN111886253B (https=)
AR (1) AR114127A1 (https=)
AU (2) AU2019228474B2 (https=)
BR (1) BR112020015983A2 (https=)
CA (1) CA3092064C (https=)
CL (1) CL2020002180A1 (https=)
CO (1) CO2020010188A2 (https=)
CR (1) CR20200375A (https=)
DO (1) DOP2020000153A (https=)
EA (1) EA202091809A1 (https=)
EC (1) ECSP20053544A (https=)
IL (1) IL276340A (https=)
JO (1) JOP20200210A1 (https=)
MA (1) MA52414A (https=)
MX (1) MX2020009124A (https=)
PE (1) PE20210045A1 (https=)
PH (1) PH12020551463A1 (https=)
SA (1) SA520420082B1 (https=)
SG (1) SG11202008437WA (https=)
TW (1) TWI708787B (https=)
WO (1) WO2019168745A1 (https=)
ZA (1) ZA202004601B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207393B2 (en) * 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
BR112022021392A2 (pt) * 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
EP4159235A4 (en) * 2020-05-25 2024-07-10 Foundation for Biomedical Research and Innovation at Kobe PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
IL307887A (en) 2021-05-13 2023-12-01 Foundation For Biomedical Res And Innovation At Kobe Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
PE20241755A1 (es) 2021-11-19 2024-08-28 Mirobio Ltd Anticuerpos pd-1 disenados por ingenieria y usos de estos
JP2025504020A (ja) * 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024010861A2 (en) * 2022-07-06 2024-01-11 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2024040206A2 (en) * 2022-08-19 2024-02-22 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
WO2024050421A2 (en) * 2022-08-30 2024-03-07 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
TW202500583A (zh) * 2023-03-17 2025-01-01 美商美國禮來大藥廠 Pd-1促效劑抗體及以pd-1促效劑抗體治療發炎或自體免疫皮膚疾病之方法
WO2025042732A1 (en) * 2023-08-18 2025-02-27 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
CN120424213A (zh) * 2024-02-02 2025-08-05 英诺湖医药(杭州)有限公司 特异性结合pd-1的单克隆抗体及其医药用途
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742953A1 (en) * 2011-08-11 2014-06-18 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
WO2016020856A2 (en) * 2014-08-05 2016-02-11 MabQuest SA Immunological reagents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN105431449B (zh) 2013-04-05 2021-08-24 港大科桥有限公司 新的pd1同种型及其用于加强免疫应答的用途
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
HK1254803A1 (zh) 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
EA201890790A1 (ru) * 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
PL3368572T3 (pl) 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
CR20180151A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Antcuierpos anti-pd1 y métodos de uso
KR102809728B1 (ko) 2015-12-02 2025-05-21 주식회사 에스티큐브 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742953A1 (en) * 2011-08-11 2014-06-18 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
WO2016020856A2 (en) * 2014-08-05 2016-02-11 MabQuest SA Immunological reagents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Li T, Ma R, Zhu JY, Wang FS, Huang L, Leng XS. PD-1/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance. Transplant Proc. 2015;47(1):165–70. *

Also Published As

Publication number Publication date
CO2020010188A2 (es) 2020-08-31
BR112020015983A2 (pt) 2020-12-15
AU2019228474B2 (en) 2023-04-13
IL276340A (en) 2020-09-30
CL2020002180A1 (es) 2021-01-04
US10493148B2 (en) 2019-12-03
AU2019228474A1 (en) 2020-08-20
ZA202004601B (en) 2022-03-30
EA202091809A1 (ru) 2020-11-23
AR114127A1 (es) 2020-07-22
KR20200115614A (ko) 2020-10-07
TW201942133A (zh) 2019-11-01
JP2022088411A (ja) 2022-06-14
CN111886253A (zh) 2020-11-03
CN118806891A (zh) 2024-10-22
AU2023204569A1 (en) 2023-10-26
KR102536014B1 (ko) 2023-05-24
SA520420082B1 (ar) 2022-11-11
WO2019168745A1 (en) 2019-09-06
ECSP20053544A (es) 2020-10-30
MA52414A (fr) 2021-01-06
JP2021516235A (ja) 2021-07-01
NZ766604A (en) 2024-10-25
CN118846042A (zh) 2024-10-29
MX2020009124A (es) 2020-09-28
SG11202008437WA (en) 2020-09-29
JP7071521B2 (ja) 2022-05-19
CA3092064A1 (en) 2019-09-06
PE20210045A1 (es) 2021-01-08
JP2023093549A (ja) 2023-07-04
CN118903407A (zh) 2024-11-08
KR20230079458A (ko) 2023-06-07
CN111886253B (zh) 2024-08-27
JP7259107B2 (ja) 2023-04-17
PH12020551463A1 (en) 2021-09-01
EP3759139A1 (en) 2021-01-06
CA3092064C (en) 2024-01-02
US20190270818A1 (en) 2019-09-05
JOP20200210A1 (ar) 2020-08-30
DOP2020000153A (es) 2020-09-15
CR20200375A (es) 2020-09-25

Similar Documents

Publication Publication Date Title
TWI708787B (zh) Pd-1促效劑抗體及其用途
JP7366543B2 (ja) Ｂｃｍａ結合分子及びその使用方法
RU2732042C2 (ru) Анти-pvrig антитела и способы применения
EP3081576B1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI800694B (zh) 拮抗性cd40單株抗體及其用途
CN111526888A (zh) 抗tigit抗体及其作为治疗和诊断的用途
JP7450743B2 (ja) 抗ヒトｃｄ１９抗体
JP2019522624A (ja) 抗ｐｄ−ｌ１−抗ｔｉｍ−３二重特異性抗体
US20240269276A1 (en) Specific binding protein targeting pd-l1 and cd73
EA044114B1 (ru) Агонистические антитела против pd-1 и их применение
TW202434625A (zh) Lag-3及pd-1/lag-3抗體
EA048356B1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28